Adial pharmaceuticals announces peer-reviewed publication highlighting promising safety data and high patient compliance in a clinical trial of ad04 as a potential treatment for alcohol use disorder

Findings underscore the liver safety of ad04 as compared to placebo in the prior phase 3 clinical trial findings underscore the liver safety of ad04 as compared to placebo in the prior phase 3 clinical trial
ADIL Ratings Summary
ADIL Quant Ranking